The findings revealed that CENPW exhibited significantly higher expression levels in breast cancer, cervical cancer, lung cancer, stomach cancer, esophageal cancer, colon cancer, rectum cancer, head and neck squamous cell carcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, thyroid carcinoma, glioblastoma multiforme, and bladder urothelial carcinoma compared to their respective normal tissues (Figure 1). This evidence concerns the gene CENPW and bladder transitional cell carcinoma.